Venous Thromboembolism – Epidemiology – Middle East & Africa
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE for each country, as well as annualized event counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan; we use 10 years for the rest of the countries.
Clarivate Epidemiology's VTE forecast will answer the following questions:
Of all diagnosed VTE events, how many in each country are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?
How will improvements in healthcare access and diagnostic technology affect the epidemiology of VTE in the low-income countries over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts eight VTE patient populations as follows:
Venous Thromboembolism - Epidemiology - Middle East & Africa
Diagnosed Incidence of Venous Thromboembolism Among People of All Ages in 2021 and 2031
Relative Sizes of Factors Contributing to the Trend in Diagnosed Incidence of Venous Thromboembolism Over the Next 10 Years
Analysis of the Diagnosed Venous Thromboembolism Events by Etiology
Diagnosed Events of Venous Thromboembolism
Venous Thromboembolism Events by Etiology
Venous Thromboembolism Events by Cancer Association
Venous Thromboembolism Events by Recurrence
Studies Included in the Analysis of Venous Thromboembolism
Studies Excluded from the Analysis of Venous Thromboembolism
Risk/Protective Factors for Venous Thromboembolism
Sunali D. Goonesekera, S.M.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.
Emma McFadden, Ph.D.
Emma McFadden, Ph.D., is a director on the CNS/Ophthalmology Disorders team at Clarivate. Her focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored reports in a number of other indications, including multiple sclerosis and epilepsy. Dr. McFadden earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College in Dublin.